Quantcast
Last updated on April 18, 2014 at 16:29 EDT

Latest Polaris Group Stories

2011-07-28 07:00:00

SAN DIEGO, July 28, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a pivotal Phase 3 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in hepatocellular carcinoma (HCC) patients. Over 600 patients who have failed prior systemic therapy will be enrolled in the randomized, double-blind, placebo-controlled study at sites in China, Taiwan, the United States, Italy and the U.K.. Patients will...

2011-05-18 07:00:00

NEW YORK and SAN DIEGO, May 18, 2011 /PRNewswire/ -- Ludwig Institute for Cancer Research LTD (LICR) and Polaris Group (Polaris) today announced the formation of a collaboration to expand development of Polaris' novel cancer drug, pegylated arginine deiminase (ADI-PEG 20). ADI-PEG 20 kills tumor cells by depletion of the amino acid arginine. As part of the collaboration, LICR and Polaris will explore further the potential of ADI-PEG 20 as a cancer therapy and aim to identify other amino...

2011-05-12 07:00:00

SAN DIEGO, May 12, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that the Company will highlight clinical development plans for its Phase 3-ready pegylated arginine deiminase, ADI-PEG 20, during a symposium held on Tuesday, May 24, at 1:30 p.m. China Standard Time in Taipei, Taiwan. Details about Polaris' upcoming pivotal Phase 3 clinical trial of ADI-PEG 20 in hepatocellular carcinoma (HCC) will be presented by the principal investigator, Ghassan Abou-Alfa, M.D., of...

2011-04-11 09:13:00

SAN DIEGO, April 11, 2011 /PRNewswire/ -- Polaris Group (Polaris) announced today that data from preclinical studies of ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, is synergistic with hydroxychloroquine (ChQ) in a human pancreatic cancer cell line and with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in human melanoma cell lines. Both ChQ and TRAIL are known inhibitors of autophagy. These results support the commencement of Phase 1/2 clinical...

2011-04-08 07:00:00

SAN DIEGO, April 8, 2011 /PRNewswire/ -- Polaris Group (Polaris) announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer. These cancers have a high incidence of deficiencies of the arginine synthesis enzyme argininosuccinate synthetase (ASS) due to hypermethylation at the promoter of the gene that codes for ASS...

2011-03-31 07:00:00

SAN DIEGO, March 31, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that the U.S. Food & Drug Administration (FDA) has approved the company's Special Protocol Assessment (SPA) for a Phase 3 clinical trial of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced hepatocellular carcinoma (HCC). The randomized, placebo-controlled, global trial will enroll approximately 600 patients who have failed prior systemic chemotherapy. The primary endpoint of the study...

2011-03-18 08:52:00

SAN DIEGO, March 18, 2011 /PRNewswire/ -- Polaris Group announced today the enrollment of the first patient in a Phase 2 clinical trial of ADI-PEG 20 (pegylated arginine deiminase), the company's novel enzyme-based treatment for malignant mesothelioma. This randomized trial, called "ADAM" (Arginine Deiminase And Mesothelioma), will evaluate the treatment efficacy of ADI-PEG 20 as a single agent compared to the best supportive care. The primary endpoint of the study is progression free...

2011-03-15 16:21:00

SAN DIEGO, March 15, 2011 /PRNewswire/ -- Polaris Group today announced the appointment of Robert E. Hoffman as chief financial officer. Hoffman has joined Polaris from Arena Pharmaceuticals Inc., where he held senior financial positions for more than 13 years. Most recently, Hoffman was vice president of finance and chief financial officer. In his leadership roles, Hoffman contributed to the success of Arena's initial public offering in 2000 and other equity, debt and collaborative...

2011-02-14 07:00:00

NEW YORK and SAN DIEGO, Feb. 14, 2011 /PRNewswire/ -- Polaris Group (Polaris) and The Ludwig Institute for Cancer Research (LICR) today announced the enrollment of the first patient in a Phase 2 clinical trial evaluating ADI-PEG 20 in the treatment of small cell lung cancer (SCLC). The trial, sponsored by LICR, is enrolling patients at Memorial Sloan-Kettering Cancer Center and Duke University Medical Center and will soon commence at St. Bartholomew's Hospital in London. This study will...

2010-06-07 08:00:00

SAN DIEGO, June 7 /PRNewswire/ -- Physicians attending the annual meeting of the American Society of Clinical Oncology (ASCO) presented evidence that pegylated arginine deiminase (ADI-PEG 20), a novel anticancer drug that targets ASS(-) tumors, and which is being developed and manufactured by Polaris Group, was effective in inhibiting the growth of metastatic melanoma cells. Dr. L.G. Feun from the University of Miami, Miami, FL presented results from a phase II trial in 36 metastatic...